Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus

The approval of Novo Nordisk's (NYSE:NVO) oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.• What should traders watch with XLV?Broad funds like the Health Care Select Sector SPDR Fund (NYSE:XLV) and the Vanguard Health Care ETF (NYSE:VHT) offer diversified exposure to major drugmakers, such as Novo Nordisk and Eli Lilly And Co (NYSE:LLY) , as well as insurers and health care ...